The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.

The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update. Discov Med. 2020 May-Jun;29(158):191-199 Authors: Gurram S, Al Harthy M, Ball MW Abstract Treatment options for metastatic renal cell carcinoma (RCC) continue to expand. Three recent phase III trials, Checkmate 214, Keynote-426, and Javelin Renal 101, have led to FDA approval of three new regimens for patients with clear cell RCC: nivolumab plus ipilimumab, pembrolizumab plus axitinib, and avelumab plus axitinib, respectively. At the same time, the dearth of treatment options for non-clear cell RCC has changed very little. The role of cytoreductive nephrectomy has also come into question after the publication of the CARMENA and SURTIME trials. This review will examine recent changes in therapeutic options in clear cell RCC and non-clear RCC, and the role of surgery in the treatment of metastatic RCC. PMID: 33007194 [PubMed - as supplied by publisher]
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research